Company facts: Rhone-Poulenc
Article Abstract:
Rhone-Poulenc ranks first among chemicals companies in France, and has moved into healthcare, away from cyclical chemicals activities. The company has not many basic chemicals activities so has not benefited from a rise in the price of chemicals, while input prices have risen. Rhone-Poulenc's subsidiary, Rhone-Poulenc Rorer, has made a bid for Fisons which would create a strong group in the rapidly growing market for respiratory treatments. Margins should be helped by an easing of prices of commodity chemicals.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Hoechst aims for spin-off
Article Abstract:
Hoechst aims to spin off its pharmaceuticals businesses by 2000, according to Jurgen Dormann, chief executive. The company ranks second in the world drugs market in terms of sales. A spin-off could lead to a re-rating of the group's shares, since investors tend to give a higher rating to such shares when they are hived off into a separate company. Bayer could carry out a similar move in order to enhance its share value. The alliance between Sandoz and Ciba means that restructuring is more likely to occur.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Rhone sounds early warning
Article Abstract:
Rhone Poulenc has stated that results for 1995 will be lower than anticipated. The company's 1995 profit is scheduled for release by Jan 31 1996. External factors such as strikes among public sector employees in France and slower economic growth have affected results, but there is also concern over provisions. A JV has been set up with Hoechst which will operate in the US and will produce plasma and blood products for transplants and hemophilia treatments.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Company facts: Roche. Roche: mixed week. Company facts: Merck
- Abstracts: Get out of accounts that gather dust. Investing for income: all roads carry risk. Long wait for Midshires money
- Abstracts: British Assets Trust: dubious asset. Kleinwort trust cash escape. Kleinwort European Privatisation Trust: Euro vision
- Abstracts: Flea collars and peat held back profits. Amberley. Animal house